Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.56), $0.03 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $358 thousand versus the consensus estimate of $5.42 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.